HULUWA(605199)2024-08-30 10:34Sales Performance - The sales of pediatric lung heat cough granules increased by 50% in the first half of the year, driven by strong demand in the medical sector, especially during the winter and around the Spring Festival [3] - The sales of Ke Ke Pian, another core product, approached 50 million yuan, showing a slight decline compared to the same period last year due to tight supply of raw materials [3][5] - The company expects sales of core products to increase in the autumn and winter seasons, particularly after September, due to a rise in respiratory diseases [3][4] Product Development - In the first half of 2024, the company received production registration approvals for 7 products and passed consistency evaluations for 2 products, with 34 new products under application [4] - The company is focusing on four strategies for research and development: targeting children's health, deepening traditional Chinese medicine, expanding indications, and aligning with national policy directions [4] Future Growth Potential - The company is cultivating potential products to enrich its product line, with the compound lysine granules being a key focus for the children's health market [4] - The introduction of new packaging for the intestinal inflammation granules aims to cater to both children and adults, expanding market reach [4] - The company is leveraging the advantages of the Hainan Free Trade Port to promote export business, contributing to future growth [4][5] Raw Material Supply - In May 2023, the company acquired a 51% stake in Jiangxi Rongxing Pharmaceutical to stabilize the supply and price fluctuations of raw materials [5] - The company plans to produce more raw materials for its formulations at Jiangxi Rongxing, enhancing its upstream supply chain [5]